-
Sector Analysis
Resistant Hypertension: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034
Understand the Future of the Resistant Hypertension Market The resistant hypertension (RH) therapeutics market is entering a new phase of growth as unmet medical needs, evolving treatment strategies, and pipeline innovation reshape the competitive landscape. This report provides a detailed analysis of the RH market across the 7MM (US, 5EU, and Japan), supported by an Excel-based forecast model through 2034. The report highlights a projected increase in diagnosed prevalent cases of resistant hypertension across the forecast period, alongside growing demand...
-
Thematic Analysis
FDI Trends in LATAM (2025)
Foreign Direct Investment (FDI) in the Latin American (LATAM) region is projected to increase in 2025, sculpted by commodity demand, competing US-Chinese investments, and expanded bilateral trade agreements conductive of FDI inflows. According to GlobalData’s FDI database, opened Greenfield FDI projects are projected to increase by ~1.8% in 2025, preceding consecutive years of growth in 2022, 2023 and 2024. Bucking the global trend, Foreign Direct Investment (FDI) in the Latin American (LATAM) region is projected to increase in 2025, sculpted...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis (IPF) Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7 major markets and provides an Excel-based forecast model for the Idiopathic Pulmonary Fibrosis (IPF) market through 2034. GlobalData estimated that drug sales for IPF in 2024 were approximately $2.7 billion across the 7MM, with the market size anticipated to grow to approximately $5.8 billion by 2034, at a compound annual growth rate (CAGR) of 7.7%. Major drivers of growth during the forecast period include the launches of several pipeline agents, most notably Jascayd (nerandomilast), Tyvaso...
-
Sector Analysis
Cell and Gene Therapies in Respiratory Disorders: Therapeutic Analysis, Treatment Options, Regulations, Sales Forecast and Future Market Assessment
The cell and gene therapies (CGTs) landscape for respiratory diseases is currently in the early stages of development, with no marketed CGTs to date.
-
Sector Analysis
Diabetic Macular Edema (DME): Epidemiology Forecast to 2034
Diabetic macular edema (DME) is a vision-threatening complication of diabetes that is a major cause of vision impairment in diabetic individuals and is characterized by fluid accumulation in the macula due to a breakdown of the blood retinal barrier (BRB) (Cheema and Cheema, 2024). DME manifests as retinal thickening caused by the accumulation of intraretinal fluid, primarily in the inner and outer plexiform layers. It can occur due to hyperpermeability of the retinal vasculature. DME can occur with any level...
-
Sector Analysis
Insomnia: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2032
Understand the Future of the Insomnia Therapeutics Market The insomnia therapeutics market continues to evolve as treatment innovation, unmet patient needs, and changing prescribing patterns reshape the competitive landscape. This report provides a comprehensive analysis of the insomnia market across the 7MM, supported by an Excel-based forecast model covering the period from 2022 to 2032. Z-drugs remain the most common first-line treatment across the US and 5EU markets, while the current pipeline remains limited but diverse, featuring products with varying...
-
Sector Analysis
Bipolar Disorder: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034
This report covers the 7MM and provides an Excel-based forecast model for the Bipolar Disorder market through 2034. The bipolar disorder market is crowded with inexpensive generic products and off-label drugs.There are currently not many effective treatments targeting bipolar depression, warranting targeted drug development. In the late-stage pipeline (Phase IIb onwards), there are four products being developed to target the depressive polarity of bipolar disorder. The BD market across the 7MM was valued at $5.6 billion in the 2024 baseline...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, December 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Thematic Analysis
Cell and Gene Therapy Investment Trends: Strategic Intelligence
Report Value Proposition – Why Does the Cell & Gene Therapy Investment Landscape Matter? Cell and gene therapies (CGTs) are transforming the treatment of genetic diseases, oncology, hematological disorders, and neurological conditions, creating one of the most dynamic areas of biopharmaceutical innovation. As the market matures, investors are shifting their focus toward scalable technologies, manufacturing capabilities, platform innovation, and commercially viable therapeutic programs. GlobalData's Cell & Gene Therapy Investment Trends report provides a comprehensive analysis of the evolving CGT investment...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, November 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.